Please assess the completion status of the following clinical trial:

Trial Title: Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) treated with a prior allogeneic transplant \>2 years previously~* Persons currently receiving Naglazyme may be accepted into the study~* Age \> 2 years~* \>10% engrafted based on most recent testing~* Willing to commit to traveling to the University of Minnesota every 6 months~* Written informed consent with parent/guardian consent for children \< 18 years of age or persons unable to consent with minor assent if appropriate~Exclusion Criteria:~* History of cardiac or pulmonary insufficiency or those requiring continuous supplemental oxygen~* Pregnant or breastfeeding~* Any condition that, in the view of the investigator, places the patient at high risk of poor treatment compliance or of not completing the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naglazyme® (Type: EXPERIMENTAL): weekly Naglazyme® infusion for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).